.svg)
.png)
Clinical supply isn't measured by how well a study was planned. It's measured by whether patients get drug; on time, without waste, and without avoidable cost. That gets harder every year.
Supply strategies now span global depot networks, cold chain logistics, comparator sourcing, and increasingly complex distribution models. Demand signals shift as enrollment evolves. Protocols change mid-study. Regions open and close. For supply teams, this isn't disruption, it's normal operations.
The question is no longer whether trials are complex. It's whether your RTSM can keep supply aligned to demand without increasing risk, waste, or cost. Too often, it can't.
Today's trials operate within coordinated supply ecosystems that include global depot and 3PL networks (often with cold chain requirements), regional comparator sourcing strategies, packagers and central pharmacies working in parallel, and adaptive distribution models that respond to enrollment behavior. Every handoff carries chain-of-custody and compliance obligations that cannot bend.
Against that backdrop, supply teams balance a set of performance metrics that rarely move in the same direction: service levels at the site and patient level, waste and expiry rates across depots and regions, inventory buffers versus overproduction risk, and total trial supply spend. What matters isn't whether the plan looked good at study start. It's whether supply stays aligned to demand as reality changes.
Most RTSM platforms were not built with supply execution as the priority. They were built for control: lock the configuration, define fixed paths, limit change.
That model struggles when supply must continuously adapt. In practice, teams work around the system; tracking inventory risk and redistribution needs outside the RTSM, revalidating configurations to support routine adjustments, and manually coordinating site transfers and depot balancing that the system can't handle. Because supply sits at the intersection of Clinical Operations, QA, Regulatory, Procurement, and external logistics partners, that workaround burden doesn't stay with one team. It compounds across functions.
The result isn't just inefficiency. It's increased cost, increased risk, and reduced confidence in supply decisions.
When systems can't adapt to supply reality, the impact is measurable. Conservative buffers and limited visibility drive excess production. Redistribution delays turn into expiry write-offs. Lagging demand signals create stockouts or near-misses. Reactive resupply generates emergency shipping costs. And every manual coordination cycle across stakeholders adds overhead that compounds with every protocol change.
Endpoint Clinical built its RTSM platform, Elosity, around a reality the industry has been slow to accept: in modern trials, change isn't the exception — it's the operating condition.
Most RTSM platforms treat change as an exception to be managed. Elosity treats it as the operating condition. That distinction shapes everything — from how the system is architected to how supply teams interact with it day to day.
Rather than forcing supply teams to work around rigid configurations, Elosity is designed to operate within real-world supply environments: multi-tier depot and pharmacy networks, regional and dynamic sourcing strategies including comparator management, integrated cold chain workflows, connected studies where inventory continuity matters, and full chain-of-custody visibility across every supply movement.
The result is a system built for execution, not just control — one that keeps supply aligned to demand as protocols evolve, enrollment shifts, and regions open and close. This isn't about simplifying the supply strategy. It's about enabling execution within the complexity that already exists.
In live trials, supply decisions need to evolve constantly. The difference is whether the system treats change as disruption or as controlled execution.
With Elosity, supply teams can adjust strategies as demand signals shift, rebalance inventory across regions and depots before risk escalates, support site-to-site and cross-region transfers with full traceability, and update supply logic without triggering rebuilds or revalidation cycles. Change happens faster, with less manual coordination and no new compliance exposure.
Supply teams don't just need reporting. They need decision-grade visibility; insight that tells them not just what happened, but what to do next.
Elosity provides real-time views of inventory levels, movement, and exposure across the network, along with distribution paths and partner activity across depots, 3PLs, and pharmacies. Critically, it shows the impact of supply changes on service levels, buffers, and risk before decisions are finalized. Human-readable audit trails, embedded governance, and role-based workflows mean teams can act quickly without adding layers of manual oversight, and compliance stays intact without slowing execution.
When the system can keep pace with supply reality, the results are tangible: lower waste and expiry exposure, better alignment between supply and demand, fewer reactive shipments, reduced coordination burden across functions and partners, and the confidence to make changes without fear of breaking the system.
Elosity doesn't reduce the complexity of modern clinical supply. It enables teams to execute within it; more efficiently, more predictably, and with less risk.
Endpoint Clinical's Elosity platform is purpose-built for the complexity modern trials demand — from dynamic depot and sourcing strategies to cold chain workflows and full chain-of-custody visibility. No rebuilds. No revalidation cycles. No drag.
.png)
Why Modern Supply Execution Needs a Different Kind of RTSM
.png)
Change is inevitable in clinical trials. Chaos is not.
.png)
Lessons from the Glasgow Clinical Research Facility
